Codon

NOVEMBER 3, 2024

Still, while these developments provide cause for hope, each drug or vaccine faces a variety of challenges, ranging from financial incentives for clinical trials to the difficulty of discovering new antimicrobials that pass safety and efficacy tests. A phase 3 clinical trial for M72/AS01E, funded by the Gates Foundation, began this year.

Vaccine 102

Vaccine Trials Therapies Treatment 102

Dark Matter Blog

AUGUST 27, 2020

A few years ago, at Arrakis Therapeutics, we set out to conquer a strange new territory, drugging RNA structures with small molecules. In fact, it was these early pharmaceutical successes that gave us the confidence that we would ultimately succeed in systematically drugging a wide range of RNA structures.

Small Molecule 52

Small Molecule RNA Clinical Trials Drugs 52

Codon

AUGUST 26, 2024

One large-scale clinical trial found that it only reduces the relative risk of death by about ten percent in hospitalized patients. Remdesivir and other broad-spectrum antivirals work by jamming up RNA-dependent RNA polymerase (RdRp), an enzyme that nearly all RNA viruses use to replicate their genomes.

RNA 102

RNA Virus DNA Vaccine 102

The Pharma Data

DECEMBER 10, 2020

Moderna has begun dosing adolescents in a phase 2/3 trial evaluating messenger RNA-based vaccine candidate mRNA-1273 and plans to enroll 3,000 U.S. participants aged 12 to 17. Source link.

Vaccine 52

Vaccine Trials RNA Research 52

Vial

DECEMBER 5, 2023

Transforming Genomics Research Next-generation sequencing (NGS) enables comprehensive genome sequencing and has transformed genomics research, offering vastly improved capabilities for analyzing DNA and RNA in a high-throughput and cost-effective manner. Fountzilas et al.

Clinical Trials 52

Clinical Trials Trials RNA Bioinformatics 52

Drug Target Review

APRIL 26, 2023

Scientists from the Massachusetts Institute of Technology (MIT) and the University of Massachusetts Medical School (UMass), US, have collaborated to create a novel type of nanoparticle that can deliver messenger RNA that encodes for beneficial proteins to the lungs.

RNA 98

RNA Medical Schools Engineering Disease 98

The Pharma Data

DECEMBER 14, 2020

Supported by promising phase 1 data, CureVac announced Monday that it has enrolled the first participant in the pivotal phase 2b/3 study of its messenger-RNA based coronavirus vaccine, CVnCoV. We are hopeful that this trial will continue to demonstrate the impact of mRNA technology,” said CureVac CEO Franz-Werner Haas. James Miessler.

Vaccine 52

Vaccine Trials Immune Response RNA 52

DrugBank

MARCH 12, 2025

Introduction Messenger RNA (mRNA) technology has emerged as one of the most significant medical breakthroughs. This approach can be personalized for each patient by sequencing the tumor's DNA and RNA to identify unique mutations. At DrugBank, we also support researchers by integrating with clinical trial data.

Vaccine 97

Vaccine Treatment Clinical Trials Therapies 97

The Pharma Data

MARCH 8, 2021

Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally-bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

DECEMBER 8, 2020

8, 2020 — AstraZeneca’s COVID-19 vaccine is safe and effective, new data from late-stage trials shows. The interim findings are from phase 3 trials in the United Kingdom and Brazil that included more than 11,600 participants. TUESDAY, Dec. 8 in The Lancet. New data posted Tuesday on the U.S. © 2020 HealthDay.

Vaccine 52

Vaccine Trials Immune Response RNA 52

Fierce BioTech

MARCH 14, 2025

Join us for an exclusive webinar exploring groundbreaking findings from the DUTRENEO trial, which evaluated the role of predictive biomarkers in guiding neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). Don't miss this opportunity to gain deep insights from leading experts in oncology and biomarker research. Click here to login.

RNA 59

RNA Clinical Trials Therapies Trials 59

The Pharma Data

JUNE 26, 2021

BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced that the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial (2020-002195-12; NCT04526899). The trial is enrolling a total of 120 patients and will evaluate the effects of the combination as well as single agents alone.

Clinical Trials 52

Clinical Trials Trials Immune Response Vaccine 52

The Pharma Data

NOVEMBER 18, 2021

At the recommendation of the eDMC, Merck is stopping dosing in the trial, with continued monitoring of study participants. In light of the findings from the MK-8507-013 study, Merck conducted a review of trends in total lymphocyte and CD4+ T-cell counts in company-sponsored clinical trials of ISL across all indications and dosing regimens.

Clinical Trials 52

Clinical Trials Treatment Trials RNA 52

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

OCTOBER 25, 2021

At 48 weeks, both trials met their primary efficacity endpoint of chance of actors with HIV-1 RNA situations ? The safety and tolerability profile of DOR/ ISL during the trials to date are harmonious with the preliminarily reported Phase 2 studies. Merck Research Laboratories. “

Treatment 52

Treatment Trials RNA Clinical Trials 52

Drug Target Review

NOVEMBER 29, 2023

Our primary focus is to design and develop RNA therapies for liver diseases. By doing this, we get a superior understanding of which therapies will and will not work in human biology before a clinical trial. What does Ochre Bio do, can you give me an overview of your work?

Therapies 102

Therapies Disease RNA Engineering 102

The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. 37% of trial volunteers are from racial and ethnic minorities.

Clinical Trials 52

Clinical Trials Vaccine Trials FDA Approval 52

Drug Target Review

AUGUST 28, 2024

We then incubate the cells to mature into ‘pro-regenerative’ macrophages and insert two RNA messages to produce two human proteins that will be expressed at the site of injury when these ‘engineered’ macrophages are given back to the patient.

Therapies 116

Therapies Disease Engineering Medical Schools 116

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The Companies expect interim results from this trial in the third quarter of 2021. About the Phase 1/2 clinical trial. Expected to enroll 415 participants; interim results expected in Q3 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Broad Institute

JUNE 27, 2024

CRISPRoff silences the targeted gene by adding methyl groups, chemical tags that prevent the gene from being transcribed or read into RNA and so from being expressed as protein. CRISPRoff uses building blocks from CRISPR gene editing technology, including the guide protein Cas9 that directs the tool to the target gene.

Disease 142

Disease Therapies Engineering Clinical Trials 142

Alta Sciences

FEBRUARY 19, 2025

The guidance ensures that these targeted evaluations help identify and mitigate safety concerns early in the development process, supporting the safe progression of oligonucleotide therapies into clinical trials. An oligonucleotide is a short strand of nucleotides, the building blocks of DNA or RNA, used in genetic research and therapy.

Drug Development 52

Drug Development Clinical Pharmacology Immune Response Drugs 52

The Pharma Data

AUGUST 16, 2021

The antiviral agent incorporates RNA-like building blocks into the RNA genome of the virus. If this genetic material is further replicated, defective RNA copies are produced and the pathogen can no longer spread. Molnupiravir is currently being tested in clinical trials. ” Mutations in the genome stop the virus.

RNA 52

RNA Virus Clinical Trials Drugs 52

LifeSciVC

JANUARY 16, 2024

Whether trial design, execution, or otherwise, drug development even where there is precedent is a challenging road and should not be taken for granted. Additional trials (e.g., The incretins as a class also look interesting across a number of follow-on indications, as evidenced by clinical trials in these areas (below).

Small Molecule 140

Small Molecule Trials Therapies Disease 140

Tebu Bio: Drug Discovery

APRIL 24, 2020

mRNA vaccines are developing very quickly with dozens of ongoing clinical trials against cancers or infectious diseases (e.g. Nevertheless, researchers are now considering using messenger RNA (mRNA) technologies for the development of prophylactic and therapeutic vaccines. Pre-clinical and clinical trials […]

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

Broad Institute

AUGUST 19, 2024

Using RNA sequencing and working with the Broad’s Metabolomics Platform and collaborators at St. At the Ragon Institute, Kwon’s lab is working to move this research toward a human clinical trial. “We When she cultured different strains of lactobacilli with oleic acid, she found that oleic acid inhibited growth of L.

Hospitals 121

Hospitals Treatment Medical Schools Science 121

Broad Institute

NOVEMBER 7, 2023

To “deconstruct” RA pathology on a cellular level, the researchers combined surface protein data and histologic analysis with multiple forms of single-cell RNA-sequencing and bulk RNA sequencing. Clinical trials going forward will benefit greatly from assessing tissue characteristics alongside responses to a therapy.

Treatment 96

Treatment RNA Hospitals Disease 96

The Pharma Data

JUNE 25, 2021

To identify strains causing COVID-19 infections within the trial, sequencing of virus variants has so far been performed on 474 COVID-19 cases, of which 124 fulfilled adjudication criteria and were included in the present efficacy analysis. Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively.

Vaccine 52

Vaccine Trials Immune Response Virus 52

Broad Institute

OCTOBER 11, 2023

By then, a few cancer immunotherapies had entered clinical trials and only a handful had been approved by the FDA. As a first step, Manguso set his sights on treatments called PD-1 checkpoint inhibitors, which at the time had shown tremendous promise in clinical trials and would receive their first FDA approval in 2014.

Research 137

Research Immune Response Clinical Trials Therapies 137

The Pharma Data

OCTOBER 25, 2020

The messenger RNA-based vaccine, which is designed to block replication of the coronavirus, was shown to induce neutralizing antibodies and activate T-cells in hamsters and mice. The vaccine is currently being evaluated in phase 1 and 2 human clinical trials. Source link.

Vaccine 52

Vaccine Immune Response RNA Clinical Trials 52

DrugBank

JULY 24, 2024

However, the discovery of a pocket in the KRAS G12C mutation led to the development of drugs like sotorasib, showing promising results in clinical trials. Several PPI modulators have reached clinical trials, and some have even been approved for use, showcasing their potential for a wide range of diseases.

Small Molecule 98

Small Molecule Drugs Clinical Trials Therapies 98

The Pharma Data

OCTOBER 21, 2020

AT-527 is expected to be ideally suited to combat COVID-19 as it inhibits viral replication by interfering with viral RNA polymerase, a key component in the replication machinery of RNA viruses. Additionally, Atea is planning to study in a Phase 3 clinical trial the use of AT-527 in the post-exposure prophylaxis setting.

RNA 52

RNA Pharmaceuticals Virus Clinical Trials 52

Codon

DECEMBER 12, 2024

DNA and RNA molecules are also built from exclusively right-handed nucleic acids. Across the tree of life, organisms strictly require exactly one of the two chiral forms of their molecular building blocks — amino acids, nucleotides of RNA and DNA. 4 As far as we know, right-handed proteins never occur naturally.

DNA 104

DNA RNA Vaccine Virus 104

The Pharma Data

JANUARY 13, 2021

13, 2021 — A single-shot COVID-19 vaccine from Johnson & Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. The vaccine produced an immune response of all 805 clinical trial participants within two months of inoculation, according to results published Jan.

Vaccine 40

Vaccine Trials Clinical Trials Immune Response 40

PLOS: DNA Science

MAY 25, 2023

Now Avidity Biosciences has developed a candidate drug that weds a monoclonal antibody (MAb) to a short piece of RNA – a small interfering RNA (siRNA). This novel class of RNA therapeutics is called Antibody Oligonucleotide Conjugates (AOCs™). Synthesizing a bit of RNA, Levin writes, is the simple part.

Treatment 52

Treatment DNA RNA Clinical Trials 52

KIF1A

JULY 29, 2023

Genetic and RNA-based therapies seek to correct mutant KIF1A – improving its force generation, velocity, and distance traveled by increasing the ratio of healthy to mutant KIF1A. But it’s also worth considering if there are ways to make the neuron’s microtubule highways easier to traverse for mutant KIF1A.

RNA 98

RNA Clinical Trials Disease Science 98